Cardiotoxicity of cancer therapeutics: current issues in screening, prevention and therapy
In the context of modern cancer chemotherapeutics, cancer survivors are living longer and being exposed to potential comorbidities related to non-cancer side effects of such treatments. With close monitoring of cancer patients receiving potentially cardiotoxic medical therapies, oncologists and card...
Saved in:
Main Authors: | Richard Joseph Sheppard (Author), Jenna eBerger (Author), Igal A Sebag (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2013-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
by: Xiaomeng Liu, et al.
Published: (2024) -
Current understanding of the cardiotoxicity-related treatment of immune checkpoint inhibitors in breast cancer
by: Jiajing Dai
Published: (2023) -
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
by: Zoltán Szabó, et al.
Published: (2021) -
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023) -
Cardiotoxicity of doxorubicin - causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022)